Context Therapeutics is trading at $0.22 (-5.19%) in live trading on October 22, 2026, with broad-market weakness the clearest available context, not a confirmed company-specific catalyst. - The broader market, including the Nasdaq Composite, is sharply lower amid risk-off sentiment and geopolitical concerns. - No October 22 company-specific release appears; the latest listed was the September 9 CT-202 trial update. - October 21 turnover was 1.1671 million shares; current-session volume was not established.